Results 191 to 200 of about 29,271 (207)

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

New England Journal of Medicine, 2022
Michael Wang, Wojciech Jurczak, Mats Jerkeman   +2 more
exaly  

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

Cancer Cell, 2021
George W Wright, Louis M Staudt
exaly  

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Lancet, The, 2016
Wojciech Jurczak, Mats Jerkeman, Marek Trneny   +2 more
exaly  

Ibrutinib

Reactions Weekly, 2016
openaire   +1 more source

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Cancer Cell, 2017
Michail S Lionakis, Mark J Roschewski, John A Butman   +2 more
exaly  

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2019
Tait D Shanafelt, Neil E Kay, Susan M O'brien   +2 more
exaly  

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

New England Journal of Medicine, 2018
Athanasios Dimopoulos, Alessandra Tedeschi, Judith Trotman   +2 more
exaly  

Ibrutinib and Venetoclax for First-Line Treatment of CLL

New England Journal of Medicine, 2019
Nitin Jain, Michael Keating, Jan A Burger   +2 more
exaly  

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

New England Journal of Medicine, 2013
Simon A Rule, Peter Martin, Andre H Goy
exaly  

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

New England Journal of Medicine, 2015
Steven P Treon, Kimon Argyropoulos, Gaurav Varma   +2 more
exaly